Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway

Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the PI3K-AKT mTOR pathway

US Patent 12496353 · Granted Dec 16, 2025

Assignee

No assignee recorded.

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Therapeutic vaccine for hepatitis b virus (HBV) using the HBV core antigen2025
Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV PreS1 and/or PreS22025
Therapeutic vaccine for Hepatitis B virus (HBV) using the HBV core antigen2024
Synergistic effects between auristatin-based antibody drug conjugates and inhibi2023
Synergistic effects between auristatin-based antibody drug conjugates and inhibi2023
Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV PreS1 and/or PreS22022
Anti-NTB-A antibodies and related compositions and methods2022
Therapeutic vaccine for Hepatitis b virus (HBV) using the HBV core antigen2022
Dosage and administration of non-fucosylated anti-CD40 antibodies2022
Dosage and administration of non-fucosylated anti-CD40 antibodies2021
Anti-NTB-A antibodies and related compositions and methods2019
Synergistic effects between auristatin-based antibody drug conjugates and inhibi2019